Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 18/20 | 0.43 |
| ▸ | ALPL | P05186 | 2/20 | 0.40 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.40 |
| ▸ | ALPG | P10696 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6491461 | 0.98 | QPCT (0.43) | QPCTALPLPLAAALPG | |
| Hydrochloric Acid SCHEMBL11092935 | 0.98 | QPCT (0.43) | QPCTALPLPLAAALPG | |
| SCHEMBL10831845 | 0.94 | QPCT (0.43) | QPCTALPLPLAAALPG | |
| SCHEMBL1178918 | 0.88 | — | — | |
| SCHEMBL31251980 | 0.87 | QPCT (0.48) | QPCTALPLPLAAALPG | |
| Bromide SCHEMBL6375209 | 0.86 | ALPL (0.41) | QPCTALPLPLAAALPG | |
| SCHEMBL634200 | 0.82 | CYP1A2 (0.45) | QPCTALPLPLAA | |
| SCHEMBL8591843 | 0.80 | TBXAS1 (0.44) | QPCTALPLPLAA | |
| Hydrochloric Acid SCHEMBL28293731 | 0.80 | CYP1A2 (0.44) | QPCTALPLPLAAALPG | |
| Iodide SCHEMBL28009205 | 0.80 | CYP1A2 (0.44) | QPCTALPLPLAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| EP-2170876-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF RESTENOSIS COMPRISING ISOXAZOLE DERIVATIVES | SK HOLDINGS CO LTD (KR) | 2011-12-28 | — | — | EP | claimed |
| US-20110028506-A1 | Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-02-03 | — | — | US | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| CN-105377939-A | Epoxy resin composition for fiber matrix semi-finished products | BASF SE | 2016-03-02 | — | — | CN | disclosed |
| EP-2146968-B1 | UREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-0230035-A2 | Omega-[(hetero)alkyl]benz[cd]indol-2-amines | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4619941-A | N-[(1H-imidazol-1-yl)alkyl]-1H-indolecarboxamides useful as thromboxane synthetase inhibitors and antihypertensive agents | AMERICAN CYANAMID COMPANY (US) | 1986-10-28 | — | — | US | disclosed |
| EP-0188999-A1 | Cationic reaction products from 1-aminoalkyl imidazole compounds and epihalogen hydrins | CIBA-GEIGY AG (CH) | 1986-07-30 | — | — | EP | disclosed |
| US-4576957-A | HYPOTENSIVE | AMERICAN CYANAMID COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| US-4568687-A | THROMBOXANE SYNTHETASE TNZYME INHIBITORS; HYPOTENSIVE AGENTS, CARDIOTONIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-02-04 | — | — | US | disclosed |
| US-4555519-A | Thromboxane synthetase enzyme inhibiting N-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]pyridinecarboxamides | AMERICAN CYANAMID COMPANY (US) | 1985-11-26 | — | — | US | disclosed |
| US-4507315-A | Hypoglycaemic and hypolipidaemic benzamide substituted (1H-) imidazole derivatives and compositions | MAY & BAKER LIMITED (GB) | 1985-03-26 | — | — | US | disclosed |
| EP-0117462-A2 | N-(2-4-(1H-imidazol-1-yl)alkyl)arylamides | AMERICAN CYANAMID COMPANY (US) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028506-A1 | Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives | PTGIR, GPR119, PTGIS | QPCT 2502/4885ALPL 650/4885PLAA 3430/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | QPCT 4052/4885ALPL 34/4885PLAA 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.